

## Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

- **Investment Rational**

2bPrecise delivers a smart technology infrastructure that supports genomic data management today and provides in-workflow access to valuable informational resources far into the future. When integrated as part of the compendium of patient information, this actionable dataset helps drive better diagnoses and faster treatment. 2bPrecise partners with a wide range of clients, from national institutes, to cancer centers, to IDNs.
- **Business Strategy**

Rapid growth of genetic testing, molecular profiling and genomic-based treatment has created a new, practical challenge for health systems: How to incorporate precision medicine into clinical workflows. Virtually every service line today – pediatrics, maternal fetal medicine, neurology, behavioral health, cardiology, oncology and more – seeks access to this valuable genomic information, made available and useable via 2bPrecise.
- **Core Technology**

Cloud-based, 2bPrecise consumes molecular data from labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology and delivering insights to providers within their familiar workflow. Plus, the solution is built to interact with evolving knowledge sources and care guidelines. It solves the problem of how organizations can leverage genetic/genomic data at the point of care meaningfully.
- **Product Profile/Pipeline**

2bPrecise is pursuing more than 70 leads, focusing on organizations that perform genetic/genomic testing in at least one clinical area. This provides an opportunity to discuss the demands of the resulting data set, and the need to remain current with changing science. We work as collaborators with clients to create clinical and informatics strategies according to their precision medicine priorities.
- **What's Next?**

2bPrecise is developing functionality that addresses growing precision medicine interest in four clinical areas (where testing is increasing): pediatrics, oncology, cardiology, women's health. These packages will deliver insights including genetic risk identification, precise diagnoses, pharmacogenomics and targeted molecular therapies. This provides an onramp for clients to launch a precision medicine program in one specific area and scale across their enterprise.